Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Celcuity Inc.
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer
July 18, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences
May 26, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Inc. Announces $100 Million Private Placement
May 16, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call
May 09, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences
April 05, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates
March 23, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call
March 16, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in the Cowen 42nd Annual Health Care Conference
March 02, 2022
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
January 18, 2022
From
Celcuity Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
CELC
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium
December 10, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium
December 02, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development
November 29, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial
November 15, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences
November 09, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 08, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call
October 29, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases
October 18, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 05, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
August 02, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity to Participate in the William Blair Biotech Focus Conference
July 08, 2021
From
Celcuity Inc.
Via
AccessWire
Tickers
CELC
Celcuity Announces Pricing of Follow-on Offering
June 28, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
CELC
Celcuity Announces Launch of Follow-on Offering
June 28, 2021
From
Celcuity Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Tickers
CELC
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
June 09, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
April 26, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
CELC
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling
April 12, 2021
From
Celcuity Inc.
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
CELC
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
April 08, 2021
From
Celcuity Inc.
Via
Business Wire
Tickers
CELC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.